• Heights Capital Management cut its stake in Faron Pharmaceuticals to 20.25% of voting rights on Sept. 4.
• Direct shareholding slipped to 8.95% from 9.41%.
• Voting rights via Convertible Bond instruments stayed at 11.3%, totaling 46,154,796 voting rights.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faron Pharmaceuticals Oyj published the original content used to generate this news brief on September 07, 2026, and is solely responsible for the information contained therein.